{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/8cf4cec7-5a0f-49c5-8ec9-36941b5c6b6e/657c4014c36d5d00188c4404?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":" Babson’s David Stein: “Succeeding where Theranos failed” ","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61ba0b311a8cbef1d93cf121/1727779559595-2dd44908-ea29-45ed-94a9-fa90345d15de.jpeg?height=200","description":"<p>The Sunday Times’ tech correspondent Danny Fortson brings on David Stein, chief executive of Babson Diagnostics, to talk about the importance of blood testing (4:49), why Babson is not Theranos (6:47), trying to compete with that idea (9:26), why they succeeded where Theranos failed (14:34), using a tiny amount of blood (18:23), fighting against the Theranos effect (24:37), being owned by a company they aim to disrupt (26:28), liquid biopsies (28:02), the new age of biological data (32:23), regulatory approval (37:09), and avoiding the spotlight (39:03).</p>","author_name":"The Sunday Times"}